30,222 Shares in Evolent Health, Inc. (NYSE:EVH) Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. bought a new stake in Evolent Health, Inc. (NYSE:EVH) during the 3rd quarter, Holdings Channel reports. The firm bought 30,222 shares of the technology company’s stock, valued at approximately $855,000.

Several other hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. raised its holdings in Evolent Health by 3.2% in the 2nd quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock valued at $298,000 after buying an additional 480 shares during the period. Ascent Group LLC raised its stake in shares of Evolent Health by 2.8% in the 1st quarter. Ascent Group LLC now owns 20,330 shares of the technology company’s stock valued at $667,000 after acquiring an additional 550 shares during the period. SeaCrest Wealth Management LLC lifted its holdings in shares of Evolent Health by 6.3% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock worth $195,000 after acquiring an additional 600 shares during the last quarter. American International Group Inc. boosted its position in shares of Evolent Health by 1.2% during the 1st quarter. American International Group Inc. now owns 55,402 shares of the technology company’s stock worth $1,817,000 after purchasing an additional 640 shares during the period. Finally, Arizona State Retirement System increased its holdings in Evolent Health by 2.3% in the 2nd quarter. Arizona State Retirement System now owns 29,083 shares of the technology company’s stock valued at $556,000 after purchasing an additional 649 shares during the last quarter.

Analyst Ratings Changes

EVH has been the subject of several research analyst reports. Barclays lowered their price target on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $38.00 to $16.00 in a report on Friday, November 8th. KeyCorp started coverage on Evolent Health in a research report on Friday, October 11th. They issued an “overweight” rating and a $35.00 target price for the company. JPMorgan Chase & Co. raised their price objective on shares of Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Finally, Oppenheimer cut their target price on shares of Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a research note on Monday. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $28.90.

Evolent Health Trading Down 3.3 %

NYSE EVH opened at $11.94 on Wednesday. Evolent Health, Inc. has a 52 week low of $11.91 and a 52 week high of $35.00. The firm has a 50 day moving average of $24.38 and a two-hundred day moving average of $24.08. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $1.39 billion, a PE ratio of -13.12 and a beta of 1.58.

Insider Buying and Selling

In other news, COO Emily Ann Rafferty sold 8,861 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $265,830.00. Following the sale, the chief operating officer now owns 63,408 shares of the company’s stock, valued at approximately $1,902,240. This trade represents a 12.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Seth Blackley sold 187,904 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total value of $5,637,120.00. Following the completion of the transaction, the chief executive officer now directly owns 411,924 shares of the company’s stock, valued at $12,357,720. This trade represents a 31.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 307,291 shares of company stock worth $9,290,385. Corporate insiders own 1.60% of the company’s stock.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.